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Conclusion: Silent AF in AMI severely impairs long term prognosis,
including rehospitalization for heart failure and death. Our large prospective
study suggests that silent AF screening should be improved after AMI in order
to identify patients at high risk for long term events.
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Background: Use of opioids is recommended for pain relief in patients
presenting acute myocardial infarction (AMI) but may slow antiplatelet
absorption and diminish its effects which can lead to treatment failure in sus-
ceptible individuals.
Aim: The aim of this study was to assess the potential clinical impact of
pre-hospital morphine use in ST-elevation myocardial infarction (STEMI)
patients from a nationwide French registry.
Methods: We assessed in-hospital complications and one-year survival
according to pre-hospital morphine use in the French Registry of Acute ST-
elevation and non-ST-elevation Myocardial Infarction (FAST-MI) 2010,
including 4,169 patients with AMI at the end of 2010 in 213 centres (76% of
active centres in France); 2,438 patients had STEMI or left bundle branch
block (LBBB), of whom 453 (19%) received morphine during pre-hospital
management. 
Results: Patients receiving morphine in pre-hospital management were
younger, with a higher rate of men, a lower cardiovascular risk profile, and a
lower early GRACE score (136±31 vs. 145±35, p<0.001). In-hospital compli-
cations (non-fatal re-MI, stroke, stent thrombosis, bleeding and transfusion)
and one-year mortality were not significantly different between both strategies
after adjustment. Using Cox multivariate analysis, pre-hospital morphine use
was not associated with a worse one-year survival (HR=0.69; 95%CI: 0.35 to
1.37, p=0.38). After propensity score matching (417 patients per group), one-
year survival was also similar with both strategies.
Conclusion: Pre-hospital morphine use was not associated with an
increase of in-hospital complication and one-year mortality; and, could be
more used as recommended in the current guidelines.
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Background: The benefit of anticoagulants (AC) to prevent thrombotic
complications during percutaneous coronary intervention (PCI) is well estab-
lished. In acute coronary syndrome (ACS) patients previously treated with
enoxaparin, an additional bolus of AC is not recommended if the last injection
was realized within 8 h. In this setting, many interventional cardiologists use
unfractionated heparin (UFH) at the time of sheath insertion. 
Objectives: The aim of our study was to describe local current practices
for AC use during PCI in patients already treated with enoxaparin and
admitted for ACS and to assess the biological impact of UFH addition at the
beginning of the procedure. 
Methods: A standardized survey was sent to the interventional cardiologists
of the southwest of France to investigate their practice in terms of periprocedural
AC use. In 2 centers, ACS patients previously treated with subcutaneous injec-
tion of enoxaparin within 8 h and who received intravenous UFH at the time of
sheath insertion were prospectively included and their plasma anti-Xa activity
was assessed at the sheath insertion and 30 min after UFH bolus. In-hospital
bleeding and ischemic events were collected. The adequate therapeutic window
was defined by anti Xa activity (range 0.5 to 0.9 IU/mL). Results: Among the
41 interventional cardiologists who replied, a large majority (75,6%) considered
the addition of UFH in patients who received enoxaparin within 8 h as a valid
option. 47 ACS patients were enrolled. The dose of the bolus of UFH was
highly variable from 20 to 90 UI / kg. Anti-Xa activities were above 0.9 IU/mL
in 14,9% of patients at the sheath insertion and in 72,3% of patients 30 min after
UFH injection. 2 bleeding complications occurred, both in over-coagulated
patients. No ischemic events were reported. 
Conclusion: The use of UFH in patients who already received enoxaparin
may result in over-anticoagulation and lead to bleeding complications.
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Background: Prevalence and correlates of prolonged dual antiplatelet
therapy (DAPT) in stable coronary artery disease (CAD) are unknown. Our
aims were to assess the proportion of stable CAD patients under long-term
DAPT and the correlates of its prescription, and to analyze its impact on prog-
nosis.
Methods: Between 2010 and 2011, 3691 patients with stable CAD for at
least 1 year (median 4 years) were divided in 2 groups according to their anti-
platelet therapy regimen at inclusion: patients under DAPT were compared to
those under single antiplatelet therapy (SAPT).
Results: Altogether, 868 (24%) patients received DAPT. Factors associ-
ated with long-term DAPT were a time interval since the last coronary event
<3 years, more multivessel and peripheral disease, prior drug eluting stent
implantation and markers for a lower bleeding risk (younger patients, higher
body mass index). After propensity score matching, the rate of the composite
endpoint (death, myocardial infarction, stroke) at 2 years was similar between
patients with or without DAPT: 5.5% versus 5.7% (p=0.9). The rate of
bleeding was also similar between groups: 1% versus 0.7%, respectively
(p=0.6).
Conclusions: Our study shows that a high proportion of stable CAD
patients is under DAPT in modern practice. Several correlates of DAPT were
identified. Of note and even so no increase in bleeding was observed, our
results do not support the prescription of prolonged DAPT.
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Background: In exploratory research strategy of coronary disease ranked
first exercise stress test (EST). Beyond its positive predictive value repre-
sented by the repolarization triggered by stress, it provides additional prog-
nostic and diagnostic information which includes exercise capacity especially
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